![](/img/cover-not-exists.png)
Dose-dependent decrease in hepatitis delta virus (HDV) RNA achieved with the oral prenylation inhibitor lonafarnib in a proof-of-concept, randomised, double-blinded, placebo-controlled study in patients with chronic HDV infection
Koh, C., Canini, L., Dahari, H., Cooper, S., Cory, D., Winters, M.A., Choong, I., Cotler, S.J., Kleiner, D.E., Yurdaydin, C., Heller, T., Glenn, J.S.Volume:
69
Language:
english
Journal:
Journal of Clinical Virology
DOI:
10.1016/j.jcv.2015.06.071
Date:
August, 2015
File:
PDF, 98 KB
english, 2015